What is Binimetinib Patent WO 2003 077914 About?
Patent WO 2003 077914, filed by Array BioPharma, describes novel benzimidazole compounds, including binimetinib, and their use in treating proliferative diseases such as cancer. The patent covers specific chemical structures and methods for their synthesis and therapeutic application, primarily targeting MEK kinase pathways involved in cell growth and survival [1].
When Does Binimetinib Patent Protection Expire?
The expiry date for patent WO 2003 077914 depends on various factors including potential extensions, grants in different jurisdictions, and any successful patent challenges. DrugPatentWatch.com provides detailed, up-to-date information on patent expiry for binimetinib, which is crucial for understanding when market exclusivity may end and generic versions could potentially launch [2].
How Does Binimetinib Work?
Binimetinib is a potent and selective inhibitor of MEK1 and MEK2 (mitogen-activated protein kinase kinases) [1]. These kinases are critical components of the RAS/RAF/MEK/ERK signaling pathway, which is often dysregulated in various cancers, driving tumor cell proliferation and survival. By inhibiting MEK, binimetinib disrupts this signaling cascade, leading to reduced tumor growth [1].
What Cancers is Binimetinib Used For?
Binimetinib is approved for the treatment of certain types of cancer. It is notably used in combination with encorafenib for patients with BRAF V600E or V600K mutations, as detected by an FDA-approved test. This combination therapy is indicated for unresectable or metastatic melanoma and metastatic colorectal cancer [3].
What are the Risks or Side Effects of Binimetinib?
Binimetinib can cause serious side effects, including cardiac dysfunction, ocular disorders, venous thromboembolism, and dermatologic reactions. Common side effects may include fatigue, nausea, diarrhea, vomiting, abdominal pain, and rash [3]. Patients considering or undergoing treatment should discuss potential risks with their healthcare provider.
Who Makes Binimetinib?
Binimetinib, marketed under the brand name Mektovi, is developed and commercialized by various pharmaceutical companies. It is currently associated with the companies that developed the combination therapy, including Pfizer and Array BioPharma [3].
How Does Binimetinib Compare to Other MEK Inhibitors?
Binimetinib belongs to a class of drugs known as MEK inhibitors, which target the same signaling pathway. Other MEK inhibitors, such as cobimetanib and trametinib, are also used in cancer therapy, often in combination with BRAF inhibitors. While they share a similar mechanism of action, differences in their specific binding affinities, pharmacokinetic profiles, and clinical trial outcomes can lead to distinct efficacy and safety profiles [4].
Can Generic Binimetinib Be Developed?
The development of generic binimetinib is contingent upon the expiry of its associated patents and regulatory approval. Once patent protection lapses and regulatory agencies determine bioequivalence, generic manufacturers can seek approval to market their versions of the drug. Information on patent expiry and the potential for generic entry can be found through resources like DrugPatentWatch.com [2].
What is the Clinical Data Supporting Binimetinib's Use?
Clinical trials have demonstrated the efficacy of binimetinib, particularly in combination with encorafenib, for specific cancer types. For instance, the Phase 3 COLUMBUS trial showed a significant improvement in progression-free survival and overall survival for patients with BRAF-mutant melanoma treated with the combination compared to a control arm [3].
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/
[4] https://www.ncbi.nlm.nih.gov/